Combinationtreatment of intravenous immunoglobulin and cultivated oral mucosal epithelial transplantation for ocular cicatricial pemphigoid

Yuichi Uchino, M. Uchino, J. Shimazaki

研究成果: Article

1 引用 (Scopus)

抄録

Ocular cicatricial pemphigoid (OCP) is a progressive cicatrising autoimmune disease affecting the skin and mucous membranes, including ocular surface epithelia. Although systemic immunosuppression is advocated, both progression of ocular surface inflammation and systemic side effects remain a problem. For the treatment of an active OCP, both control of autoimmune reaction and ocular surface reconstruction are necessary. We believe that the combination of intravenous immunoglobulin (IVIg) and cultivated oral mucosal epithelial transplantation (COMET) is a powerful treatment modality while minimising the risk of postoperative consequences inevitably associated with immunosuppression. A patient with OCP successfully treated by a combination of IVIg and COMET is described here.

元の言語English
ジャーナルBMJ Case Reports
DOI
出版物ステータスPublished - 2009 2 2
外部発表Yes

Fingerprint

Benign Mucous Membrane Pemphigoid
Intravenous Immunoglobulins
Transplantation
Immunosuppression
Autoimmune Diseases
Mucous Membrane
Epithelium
Inflammation
Skin
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

これを引用

@article{4b5435589f2144679f01a429460644d2,
title = "Combinationtreatment of intravenous immunoglobulin and cultivated oral mucosal epithelial transplantation for ocular cicatricial pemphigoid",
abstract = "Ocular cicatricial pemphigoid (OCP) is a progressive cicatrising autoimmune disease affecting the skin and mucous membranes, including ocular surface epithelia. Although systemic immunosuppression is advocated, both progression of ocular surface inflammation and systemic side effects remain a problem. For the treatment of an active OCP, both control of autoimmune reaction and ocular surface reconstruction are necessary. We believe that the combination of intravenous immunoglobulin (IVIg) and cultivated oral mucosal epithelial transplantation (COMET) is a powerful treatment modality while minimising the risk of postoperative consequences inevitably associated with immunosuppression. A patient with OCP successfully treated by a combination of IVIg and COMET is described here.",
author = "Yuichi Uchino and M. Uchino and J. Shimazaki",
year = "2009",
month = "2",
day = "2",
doi = "10.1136/bcr.09.2008.0979",
language = "English",
journal = "BMJ Case Reports",
issn = "1757-790X",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Combinationtreatment of intravenous immunoglobulin and cultivated oral mucosal epithelial transplantation for ocular cicatricial pemphigoid

AU - Uchino, Yuichi

AU - Uchino, M.

AU - Shimazaki, J.

PY - 2009/2/2

Y1 - 2009/2/2

N2 - Ocular cicatricial pemphigoid (OCP) is a progressive cicatrising autoimmune disease affecting the skin and mucous membranes, including ocular surface epithelia. Although systemic immunosuppression is advocated, both progression of ocular surface inflammation and systemic side effects remain a problem. For the treatment of an active OCP, both control of autoimmune reaction and ocular surface reconstruction are necessary. We believe that the combination of intravenous immunoglobulin (IVIg) and cultivated oral mucosal epithelial transplantation (COMET) is a powerful treatment modality while minimising the risk of postoperative consequences inevitably associated with immunosuppression. A patient with OCP successfully treated by a combination of IVIg and COMET is described here.

AB - Ocular cicatricial pemphigoid (OCP) is a progressive cicatrising autoimmune disease affecting the skin and mucous membranes, including ocular surface epithelia. Although systemic immunosuppression is advocated, both progression of ocular surface inflammation and systemic side effects remain a problem. For the treatment of an active OCP, both control of autoimmune reaction and ocular surface reconstruction are necessary. We believe that the combination of intravenous immunoglobulin (IVIg) and cultivated oral mucosal epithelial transplantation (COMET) is a powerful treatment modality while minimising the risk of postoperative consequences inevitably associated with immunosuppression. A patient with OCP successfully treated by a combination of IVIg and COMET is described here.

UR - http://www.scopus.com/inward/record.url?scp=84897586029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897586029&partnerID=8YFLogxK

U2 - 10.1136/bcr.09.2008.0979

DO - 10.1136/bcr.09.2008.0979

M3 - Article

AN - SCOPUS:84897586029

JO - BMJ Case Reports

JF - BMJ Case Reports

SN - 1757-790X

ER -